Navigation Links
NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
Date:9/26/2007

Company to develop for treatment of neurofibromatosis and cancer

NEW YORK, Sept. 26 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc., a privately held New York biotechnology company focused on developing drugs to treat the genetic disorder neurofibromatosis and related sporadic tumors, today announced that it has entered into a definitive agreement with Universite Louis Pasteur (ULP) and the Centre National de la Recherche Scientifique (CNRS) to in-license a novel family of Hsp90 inhibitors.

"Our preliminary evaluation of these compounds has yielded promising results in NF2 and cancer models", said Dr. Allan Rubenstein, CEO of NexGenix. "While targeting the inhibition of protein folding chaperones such as Hsp90 is an approach that is seeing success in clinical trials for cancer, this target has additionally been shown to be potentially promising for a number of therapeutic indications. We intend to evaluate this compound series for the treatment of several disorders."

Under the terms of this agreement, NexGenix will have an exclusive worldwide license to develop and commercialize the technology for human and animal therapeutic and diagnostic use from ULP and CNRS. NexGenix will be responsible for all development and commercialization costs and activities. In return, ULP and CNRS will be entitled to certain maintenance fees, milestone payments and royalties.

The company has additionally entered into a Collaborative Research Agreement with the Institut de Sciences et d'Ingenierie Supramoleculaires at ULP to further understanding of structure activity relationships and opportunities to improve the pharmacokinetic properties of the in-licensed Hsp90 inhibitor compound series. This research program is to be conducted at ULP by Nicolas Winssinger, PhD. Dr. Winssinger is one of the inventors of the compound series and is a member of the NexGenix Scientific Advisory Board.

About NexGenix Pharmaceuticals

NexGenix Pharmaceu
'/>"/>

SOURCE NexGenix Pharmaceuticals Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. WARF enters licensing agreements for stem cell products
4. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
5. Software company enters health space with RFID solutions on hold
6. Lucigen Corp. enters global licensing agreement
7. Call centers and customer service: The good, the bad, and the clueless
8. GE Healthcare enters agreement with Canadian health authority
9. Data centers: Buyers beware of over-hyped facilities
10. Data centers: Blowing smoke and raising red flags
11. Prodesse enters patent agreement with Roche

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)... Nov. 5 Wound Management...it has entered into a Letter of Intent to purchase...echnologies, Inc. (OTC Bulletin Board: VHGI). The ...sh and debt, 4,000,000 shares of WNDM and a royalt...Veriscrip technology being acquired from VHGI. W...
(Date:11/5/2009)...ov. 5 WaferGen Biosystem...loper of state-of-the-art genetic analysis systems...s joined the company,s Scientific Advisory Board. ...ercializing novel molecular diagnostics for cancer...lopment of computational biology systems for sever...
(Date:11/5/2009)...NG, Pa., Nov. 5 /PRNewswire-Asia-FirstCall/ -- BMP...one" or the "Company") today announced,that the Co...l results on,Monday, November 9, 2009, after the m...onference call at 5:00 pm ET on November 9, 2009,t...ay access the call by,dialing 1-888-713-4211 or 1-...
(Date:11/5/2009)... LASIK Surgery and vision correction experts list...tively involved at the recently concluded American...g in San Francisco, California. Dr. Stephen Brint,...avidorf, MD, Dr. Peter Rapoza, MD, Dr. Michael Rai...man, MD, Dr. Edward Manche, MD, and Dr. Parag Majm...
Breaking Biology Technology:OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4BMP Sunstone to Report Third Quarter 2009 Financial Results 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9
... and Tragara Pharmaceuticals Inc. today announced ...se to Tragara to develop and commercialize its nov...terms of the agreement S*BIO is eligible to receiv...s an upfront fee, development and sales milestone ...onally, S*BIO will perform certain preclinical act...
... (Nasdaq: NLTX ), today announced that it will f...ic peptide franchise, including CD-NP which is in ...CU-NP which is a pre-clinical compound. Nile will ...urn license rights for the compound to Dr. Cesare ... unable to continue to pursue the development of 2...
...ex: DDD ) today announced that the U. S. Food an...Response letter for its Abbreviated New Drug Appli...n, filed by SCOLR on August 5, 2008, seeks approva...t based on its patented Controlled Delivery Techno...e letter requests additional information, all of w...
Other Biology Technology:S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317 2S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317 3Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 2Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 3Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 4FDA Issues Complete Response Letter to SCOLR Pharma's Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine 2FDA Issues Complete Response Letter to SCOLR Pharma's Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine 3
(Date:11/6/2009)...h anniversary this month of the publication of On ...iological Sciences (AIBS) is publishing open acces...and his historic insights into evolution. , The t...of California, Berkeley, and James T. Costa of Wes...yths About Charles Darwin," appeared in the Octobe...
(Date:11/5/2009)...ion of Biology Teachers (NABT) will recognize Leon... at Naugatuck Valley Community College (NVCC) in W...cation Award during the NABT annual professional d...09 in Denver, Colorado. , The Evolution Educatio...f Biological Sciences,(AIBS) and Biological Scien...
(Date:11/4/2009)...n natural science) , United States Using Less ... today than it did 35 years ago, despite a 30 perc... partly attributable to alternative cooling method...stems. According to the latest USGS water use repo...ates goes to cooling thermoelectric power plants. ...
Breaking Biology News(10 mins):Biologists, educators recognize excellence in evolution education 2USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Cardiac stem cell trial seeks to treat some heart attack patients 58592 1Cardiac stem cell trial seeks to treat some heart attack patients 58592 2Cardiac stem cell trial seeks to treat some heart attack patients 58592 3Study explores how life experiences contribute to the biological changes of Alzheimers 10197 1Study explores how life experiences contribute to the biological changes of Alzheimers 10197 2Study explores how life experiences contribute to the biological changes of Alzheimers 10197 3FDA Approves PRE PEN Penicillin Allergy Test 58590 1FDA Approves PRE PEN Penicillin Allergy Test 58590 2
...ctedly from the ocean to rescue a dying coral reef...dramatic flair of comic-book superhero Batman, a b...d to death by seaweed ?although the fish was never...s at the ARC Centre of Excellence for Coral Reef S...are lost to weed were astonished when, after remov...
...tic increase in testicular cancer, now the most co...asian men, is the focus of a five-year, $5.5 milli...ublic Health researcher Tongzhang Zheng. , Testicu...his study will provide important information on po...rs,?said Zheng, professor and head of the Division...
...any of them had narrow, pointed teeth, which were ...ing them. But how did they then grind their food? ...they were helped by stones which they swallowed. I...d of ,gastric mill,. But this assumption does not ...ies of Bonn and Tübingen have now proved. Their re...
Other Biology News:Batfish to the rescue! 2Dinosaurs -- stones did not help with digestion 2Dinosaurs -- stones did not help with digestion 3
Custom siRNA, HPLC purified, annealed from Ambion
Silencer Pre-designed siRNA, standard purity from Ambion
Silencer Pre-designed siRNA, standard purity, annealed from Ambion
Silencer Pre-designed siRNA, HPLC purified, annealed from Ambion
Biology Products: